The less-well-described receptor ERβ has opposing actions on ERα function as studied in breast cancer, prostate cancer, gynecological cancers, and endocrine cancers; it is speculated to be a tumor suppressor [29,31,32,33]. Here, ESR2 is linked to neoplasm.